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According to WHO classiﬁcation, preneoplastic lesions
of lung cancer include several histological types: basal-
cell hyperplasia; squamous metaplasia; mild to severe
dysplasia; and bronchial-cell carcinoma. Heat shock
protein 60 (HSP60) is a predictive molecular marker in
several neoplasms, and is overexpressed during the
carcinogenic steps of cancers of the colon, prostate, and
uterus. By contrast, loss of HSP60 immunopositivity
could have prognostic relevance in patients with bladder
carcinoma. We obtained bronchial biopsy samples from
46 consecutive patients with a history of smoking
(mean 49 packs per year [SD 34]) who had chronic
obstructive pulmonary disease (mean postbroncho-
dilator forced expiratory volume in 1 s of 57% [22]).
Ten of 46 samples showed healthy bronchial epithelium,
whereas 12 samples showed basal-cell hyperplasia,
14 squamous metaplasia, and ten mild to severe dys-
plasia. We used mouse HSP60 monoclonal antibody in
the DAKO LSAB2 peroxidase system to do an immuno-
histochemical analysis of all samples. In samples that
tested positive for HSP60, mean epithelial expression
was 60% (5) in healthy bronchial cells (ﬁgure A, n=10)
and 60% (10) in basal-cell hyperplasia (ﬁgure B, n=11).
By contrast, mean expression was 7% (5) in squamous
metaplasia (ﬁgure C, n=2), and no expression was
recorded for samples of dysplasia (not shown) and basal-
cell carcinoma (ﬁgure D, n=10). Healthy bronchial
epithelia are present at the edges of samples of basal-cell
carcinoma and were negative for HSP60 expression
(ﬁgure D, right). Compared with healthy individuals and
patients with asthma, smokers with established chronic
obstructive pulmonary disease are at increased risk of
developing lung cancer. In view of these data, we
postulate that the loss of HSP60 immunopositivity could
be related to development and progression of bronchial
cancer, and could be a useful diagnostic and prognostic
tool in the management of this disease.
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